ArticleAmerican journal of reproductive immunology (New York, N.Y. : 1989)2026
Calcifediol Suppressed Placental Inflammation and Improved Pregnancy Outcomes by Targeting JAK/STAT Signaling Pathway in Preeclampsia.
Article in American journal of reproductive immunology (New York, N.Y. : 1989), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPreeclampsia (PE) is a pregnancy-specific syndrome, which has been recognized as a leading cause of maternal and neonatal morbidity and mortality worldwide. Calcifediol (25-hydroxy Vitamin D3) was reported to be closely associated with pregnancy outcomes such as preeclampsia, gestational hypertension, and gestational diabetes. Nevertheless, the specific role of calcifediol remains obscure in PE.
methodsThe pregnant rats were treated with L-NAME (50 mg/kg/day) to establish PE models. Histopathological injury of placental tissues was observed by HE staining. Systolic blood pressure, proteinuria, and urine volume were measured to evaluate the symptoms of PE. The neonatal birth rate, pup's body length and weight were determined to assess pregnancy outcomes. The placental cytokines and serum sFlt-1/PIGF ratio were detected by ELISA analysis. The protein levels were measured by Western blotting analysis.
resultsCalcifediol treatment alleviated the histopathological injury placental tissues of PE rats. In addition, calcifediol improves PE symptoms by attenuating hypertension, proteinuria and urine volume. Besides, calcifediol ameliorated pregnancy outcomes by enhancing live birth rate, neonatal birth length, and neonatal birth weight. Moreover, calcifediol restrained pro-inflammatory cytokines in placental tissues and facilitated serum sFlt-1/PIGF balance in PE rats. Mechanistically, calcifediol is closely associated with the inactivation of JAK/STAT signaling, as evidenced by the reduction of the phosphorylated JAK1, STAT1, and STAT3 proteins in placental tissues.
conclusionsCalcifediol elicits significant therapeutic effects in L-NAME-induced PE rat models by ameliorating PE symptoms and pregnancy outcomes, attenuating inflammatory responses and alleviating histopathological damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.